Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ ZENODOarrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
ZENODO
Preprint
Data sources: ZENODO
Zenodo
Claim

CDKN2A-Targeted Therapy for High-Grade EMPD

descriptionPublicationkeyboard_double_arrow_right Preprint Under curationPublisher:Zenodo
Authors: MedicOath Autonomous Discovery Engine;

doi: 10.5281/zenodo.19833705

CDKN2A-Targeted Therapy for High-Grade EMPD

Abstract

Open Targets identifies CDKN2A with score 0.29 for EMPD. CDKN2A encodes p16INK4a, a CDK4/6 inhibitor. Loss of CDKN2A function in EMPD could be targeted with CDK4/6 inhibitors like palbociclib, which have shown efficacy in other CDKN2A-deficient cancers.

Powered by OpenAIRE graph
Found an issue? Give us feedback